Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC) †
Titel:
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC) †
Auteur:
Joerger, M. von Pawel, J. Kraff, S. Fischer, J.R. Eberhardt, W. Gauler, T.C. Mueller, L. Reinmuth, N. Reck, M. Kimmich, M. Mayer, F. Kopp, H.-G. Behringer, D.M. Ko, Y.-D. Hilger, R.A. Roessler, M. Kloft, C. Henrich, A. Moritz, B. Miller, M.C. Salamone, S.J. Jaehde, U.